On March 20, 2023, Illumina Inc announced that it has issued the response to Carl Icahn?s public statements and letters to Illumina?s shareholders dated March 13 and March 15, 2023, stating that the Company has a successful long-term track record of innovating to fundamentally advance the understanding of biology and improve human health, the only profitable, pure-play genomics tools company in existence, commitment to excellence and successful execution includes profitable, double-digit revenue growth over the past decade. In addition, the Company stating that Icahn?s director nominees, who lack experience in, and knowledge of, the business and industry, Illumina risks jeopardizing the long-term success of its core franchise, which is primed to achieve rich, long-term shareholder returns over the next several years and beyond. Further, the Company stated that it continues to advance its innovation roadmap in support of its long-term growth trajectory and stating that it intended to file a proxy statement on Schedule 14A, with respect to its solicitation of proxies for 2023 annual meeting of shareholders.